Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) EBITDA Margin (2016 - 2025)

Veracyte's EBITDA Margin history spans 14 years, with the latest figure at 26.45% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 2293.0% year-over-year to 26.45%; the TTM value through Dec 2025 reached 11.17%, up 755.0%, while the annual FY2025 figure was 11.17%, 755.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 26.45% at Veracyte, up from 17.4% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 26.45% in Q4 2025 and bottomed at 114.07% in Q1 2021.
  • The 5-year median for EBITDA Margin is 10.83% (2023), against an average of 13.54%.
  • The largest annual shift saw EBITDA Margin crashed -7643bps in 2021 before it skyrocketed 9158bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 18.32% in 2021, then soared by 63bps to 6.75% in 2022, then plummeted by -436bps to 36.16% in 2023, then skyrocketed by 110bps to 3.52% in 2024, then surged by 652bps to 26.45% in 2025.
  • Per Business Quant, the three most recent readings for VCYT's EBITDA Margin are 26.45% (Q4 2025), 17.4% (Q3 2025), and 4.05% (Q2 2025).